In order to deeply interpret the development status of the retail pharmacy industry and judge the future trend, Zhiyan Consulting has carefully compiled and launched the "2024-2030 China Retail Pharmacy Industry Market Status Survey and Investment Prospect Analysis Report" (hereinafter referred to as the "Report"). This report is not only a comprehensive and detailed review of China's retail pharmacy market, but also the crystallization of Zhiyan Consulting's continuous tracking, on-site visits, in-depth research and accurate analysis over the years. It aims to help industry elites and investors grasp the pulse of the market more accurately, gain insight into industry trends, and provide strong support for future decision-making.
The report mainly studies the development of China's retail pharmacy industry, involving the number of retail pharmacies, the number of chain stores, the number of chain pharmacy enterprises, the chain rate of pharmacies, domestic consumption, market size and other sub-data.
The report analyzes the development of the retail pharmacy industry in an all-round way from the aspects of domestic and foreign economic environment, domestic policies, and development trends, and provides corresponding suggestions and decision-making support for industry manufacturers to grasp the industry dynamics and future innovation trends.
Retail pharmacies refer to pharmaceutical business enterprises that directly provide consumers with medicines, medical devices, health products and other medical and health products. Drugs are special, and retail pharmacies need to provide consumers with pharmaceutical services to ensure their safe use. According to the development model, retail pharmacies are mainly divided into retail chain pharmacies, retail single pharmacies and stores owned by wholesale enterprises.
The development of the pharmaceutical retail industry really began during the Tenth Five-Year Plan, that is, around 2000, the development and growth of China's chain pharmacies only took about 20 years, completing the transformation process from the era of single pharmacies to the era of chain pharmacies, and the operation and management of chain pharmacies gradually transitioned from extensive and irrational management to the stage of rational, standardized, procedural and standardized management, and the business scale and management level of chain pharmacies continued to improve, and the market concentration continued to increase.
Mainland retail pharmacies play an important role in community health services and have become the most market-oriented part of China's pharmaceutical industry chain. In 2023, the number of retail pharmacies in mainland China will increase from 447,000 in 2016 to 652,000, and the retail sales of pharmacies will increase from 340.8 billion yuan in 2016 to 622.9 billion yuan. With the gradual tightening of the Chinese government's regulatory policies on the pharmaceutical retail industry, the improvement of people's health awareness and the continuous improvement of medical standards, the scale of the consumer market of retail pharmacies will continue to expand.
The upstream of retail pharmacies are mainly suppliers of drugs, health care products and medical devices, such as Yunnan Baiyao, Hengrui Pharmaceutical, Sinopharm Holdings, Shanghai Pharmaceutical and China Resources Pharmaceutical, etc., medical device suppliers mainly include Yuyue Medical, Mindray Medical, Kaikai Medical Medical, Libang Instruments, David Medical, etc., and health care product suppliers mainly include Tomson Beijian, Beijing Tongrentang, Dong'e Ejiao, Pien Tze Huang, Harbin Pharmaceutical Co., Ltd., etc. In the middle of the industry are retail pharmacies, with representative chain pharmacy brands such as Dashenlin, Yifeng Pharmacy, Laobaimin, etc., and China's chain pharmacies occupy an increasing share in the pharmaceutical retail market. In recent years, the online transformation of chain pharmacies has accelerated, online channels such as pharmaceutical e-commerce, pharmacy APP, and official website have been gradually established, and the downstream channels of chain pharmacies have gradually increased. The downstream of the industry is the majority of consumers.
Retail pharmacies in mainland China are mainly chain pharmacies, with Sinopharm Holdings, Dashenlin, Yifeng Pharmacy, Laobaimin and other enterprises in a leading position, with a large number of stores and large revenue scale, mainly distributed in Hunan, Yunnan, Guangdong, Shanghai and other provinces and cities, for example, Hunan has Yifeng Pharmacy, Laobaimin, and Qianjin Pharmacy; Yunnan has Yixintang and Jianzhijia.
The research team of Zhiyan Consulting conducts in-depth analysis on the scale, industrial structure, key enterprises, and industrial development trends of China's retail pharmacy industry, and puts forward suggestions for the problems existing in the development of the retail pharmacy industry, providing reference for local governments, industrial chain related enterprises, and investment institutions.
Data Description:
1: The core data of this report has been updated to December 2023 (the relevant financial indicators of non-listed companies in the report are affected by corporate credit approval, and there may be a certain lag), and the forecast period of the report is 2024-2030.
2: In addition to the first-hand research information and data, authoritative data sources such as the National Bureau of Statistics, China Customs, industry associations, and public reports of listed companies (prospectuses, transfer prospectuses, annual reports, inquiry reports, etc.) also constitute the data sources of this report. The first-hand data comes from the first-hand information data obtained by the research team from interviews with key enterprises in the industry, and the main interview subjects include corporate executives, industry experts, technical leaders, downstream customers, distributors, agents, distributors and upstream raw material suppliers. Secondary sources mainly include relevant industry news, company annual reports, non-profit organizations, industry associations, government agencies and third-party databases from around the world.
3: The core data of the report is based on the strict data collection, screening, processing, analysis system and independent calculation model of the Zhiyan team to ensure the accuracy and reliability of statistical data.
4: The data used in this report are all from compliance channels, and the analysis logic is based on the professional understanding of the Zhiyan team, which clearly and accurately reflects the research views of analysts.
As a leading brand in the field of industrial consulting in China, Zhiyan Consulting takes "driving industrial development with information and empowering enterprise investment decision-making" as its brand concept. The company integrates quantitative analysis and qualitative analysis methods, uses self-developed algorithms, combines industry cross-big data, and excavates the root causes behind quantitative data through diversified analysis, analyzes the logic behind qualitative content, objectively and truthfully explains the current situation of the industry, prudently predicts the future development trend of the industry, and provides customers with professional industry analysis, market research, data insights, strategic consulting and related solutions to help customers improve their cognitive level, profitability and comprehensive competitiveness. The main services include high-quality industry research reports, special customization, monthly topics, feasibility study reports, business plans, industrial planning, etc. Provide weekly/monthly/quarterly/annual reports and other regular reports and customized data, covering policy monitoring, corporate dynamics, industry data, product price changes, investment and financing overview, market opportunities and risk analysis, etc.